Zura Bio Investor Relations Material
Latest events
Q1 2025
8 May, 2025
Q4 2024
25 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Zura Bio Limited
Access all reports
Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. It leverages multi-asset immunology to create novel dual-pathway antibodies, including tibulizumab, ZB-168, and torudokimab, which are designed to address autoimmune diseases and other conditions with unmet medical needs. These therapies have completed early-phase studies and are advancing towards further clinical development. Zura Bio Limited is headquartered in Henderson, Nevada, and its shares are listed on NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ZURA
Country
🇺🇸 United States